Irvine, CA – According to filings with the U.S. Securities and Exchange Commission, AIVITA Biomedical is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Hans Keirstead played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial products and therapeutic pipeline.

To learn more about AIVITA Biomedical, visit http://www.aivitabiomedical.com/

Contact:
Hans Keirstead, Chief Executive Officer
949-872-2555
hans@aivitabiomedical.com
https://www.linkedin.com/in/hanskeirstead/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved